Removal of the lung, pleura, diaphragm, and pericardium. Used in highly selected fit patients.
The combination of Nivolumab and Ipilimumab (CheckMate 743) was recently FDA-approved, showing improved survival over chemotherapy in non-epithelioid cases. 3. Radiation and Other Therapies
Most common; consists of cube-like cells. Associated with the best prognosis.
Research into BAP1-deficient tumors and angiogenesis inhibitors (like Bevacizumab) is ongoing.
Malignant Pleural Mesothelioma Apr 2026
Removal of the lung, pleura, diaphragm, and pericardium. Used in highly selected fit patients.
The combination of Nivolumab and Ipilimumab (CheckMate 743) was recently FDA-approved, showing improved survival over chemotherapy in non-epithelioid cases. 3. Radiation and Other Therapies malignant pleural mesothelioma
Most common; consists of cube-like cells. Associated with the best prognosis. Removal of the lung, pleura, diaphragm, and pericardium
Research into BAP1-deficient tumors and angiogenesis inhibitors (like Bevacizumab) is ongoing. Removal of the lung